Interleukin-6 plasma levels are modulated by a polymorphism in the NF-κB1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma

References

• Lossos IS, Morgensztern D. Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol 2006;24:995–1007.
   PubMed Web of Science ®Google Scholar
• Lenz G, Wright G, Dave SS, . Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008;359:2313–2323.
   PubMed Web of Science ®Google Scholar
• Linderoth J, Edén P, Ehinger M, . Genes associated with the tumour microenvironment are differentially expressed in cured versus primary chemotherapy-refractory diffuse large B-cell lymphoma. Br J Haematol 2008;141:423–432.
   PubMed Web of Science ®Google Scholar
• Seymour J, Talpaz M, Cabanillas F, . Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. J Clin Oncol 1995;13:575–582.
   PubMed Web of Science ®Google Scholar
• Blay J-Y, Burdin N, Rousset F, . Serum interleukin-10 in non Hodgkin's lymphoma: a prognostic factor. Blood 1993;82:2169–2174.
   PubMed Web of Science ®Google Scholar
• Stasi R, Zinzani PL, Galieni P, . Prognostic value of serum IL-10 and IL-2 receptor levels in aggressive non-Hodgkin's lymphoma. Br J Haematol 1994;88:770–777.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Talpaz M, Cabanillas F, . Serum levels of interleukin-10 in patients with diffuse large cell lymphoma: lack of correlation with prognosis. Blood 1995;85:2516–2520.
   PubMed Web of Science ®Google Scholar
• Voorzanger N, Touitou R, Garcia E, . Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors. Cancer Res 1996;56:5499–5505.
   PubMed Web of Science ®Google Scholar
• Fabre-Guillevin E, Tabrizi R, Coulon V, . Aggressive non-Hodgkin's lymphoma: concomitant evaluation of interleukin-2, soluble interleukin-2 receptor, interleukin-4, interleukin-6, interleukin-10 and correlation with outcome. Leuk Lymphoma 2006;47:603–611.
   PubMed Web of Science ®Google Scholar
• Smith AJ, Humphries SE. Cytokine and cytokine receptor gene polymorphisms and their functionality. Cytokine Growth Factor Rev 2009;20:43–59.
   PubMed Web of Science ®Google Scholar
• Lan Q, Zheng T, Rothman N, . Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood 2006;107:4101–4108.
   PubMed Web of Science ®Google Scholar
• Domingo-Domènech E, Benavente Y, González-Barca E, . Impact of interleukin-10 polymorphisms (-1082 and -3575) on the survival of patients with lymphoid neoplasms. Haematologica 2007;92:1475–1481.
   PubMed Web of Science ®Google Scholar
• Lech-Maranda E, Baseggio L, Charlot C, . Genetic polymorphisms in the proximal IL-10 promoter and susceptibility to non-Hodgkin lymphoma. Leuk Lymphoma 2007;48:2235–2238.
   PubMed Web of Science ®Google Scholar
• Chen Y, Zheng T, Lan Q, . Cytokine polymorphisms in Th1/Th2 pathway genes, body mass index, and risk of non-Hodgkin lymphoma. Blood 2011;117:585–590.
   PubMed Web of Science ®Google Scholar
• Cordano P, Lake A, Shield L, . Effect of IL-6 promoter polymorphism on incidence and outcome in Hodgkin's lymphoma. Br J Haematol 2005;128:493–495.
   PubMed Web of Science ®Google Scholar
• Hohaus S, Giachelia M, Di Febo A, . Polymorphism in cytokine genes as prognostic markers in Hodgkin's lymphoma. Ann Oncol 2007; 18:1376–1381.
   PubMed Web of Science ®Google Scholar
• Kube D, Hua TD, von Bonin F, . Effect of interleukin-10 gene polymorphisms on clinical outcome of patients with aggressive non-Hodgkin's lymphoma: an exploratory study. Clin Cancer Res 2008;14:3777–3784.
   PubMed Web of Science ®Google Scholar
• Habermann TM, Wang SS, Maurer MJ, . Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era. Blood 2008;112:2694–2702.
   PubMed Web of Science ®Google Scholar
• Lech-Maranda E, Baseggio L, Bienvenu J, . Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. Blood 2004;103:3529–3534.
   PubMed Web of Science ®Google Scholar
• Cerhan JR, Liu-Mares W, Fredericksen ZS, . Genetic variation in tumor necrosis factor and the nuclear factor-kappaB canonical pathway and risk of non-Hodgkin's lymphoma. Cancer Epidemiol Biomarkers Prev 2008;17:3161–3169.
   PubMed Web of Science ®Google Scholar
• Rossi D, Rasi S, Franceschetti S, . Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21. Leukemia 2009;23:1118–1126.
   PubMed Web of Science ®Google Scholar
• Rossi D, Rasi S, Di Rocco A, . The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma. Blood 2011;117:2405–2413.
   PubMed Web of Science ®Google Scholar
• Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med 2010;362:1417–1429.
   PubMed Web of Science ®Google Scholar
• Karban AS, Okazaki T, Panhuysen CI, . Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Hum Mol Genet 2004;13:35–45.
   PubMed Web of Science ®Google Scholar
• Andersen V, Christensen J, Overvad K, . Polymorphisms in NFkB, PXR, LXR and risk of colorectal cancer in a prospective study of Danes. BMC Cancer 2010;10:484.
   PubMed Web of Science ®Google Scholar
• Riemann K, Becker L, Struwe H, . Insertion/deletion polymorphism in the promoter of NFKB1 as a potential molecular marker for the risk of recurrence in superficial bladder cancer. Int J Clin Pharmacol Ther 2007;45:423–430.
   PubMed Web of Science ®Google Scholar
• Bu H, Rosdahl I, Sun XF, . Importance of polymorphisms in NF-kappaB1 and NF-kappaBIalpha genes for melanoma risk, clinicopathological features and tumor progression in Swedish melanoma patients. J Cancer Res Clin Oncol 2007;133:859–866.
   PubMed Web of Science ®Google Scholar
• Hohaus S, Giachelia M, Massini G, . Clinical significance of interleukin-10 gene polymorphisms and plasma levels in Hodgkin lymphoma. Leuk Res 2009;33:1352–1356.
   PubMed Web of Science ®Google Scholar
• Casasnovas RO, Mounier N, Brice P, . Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2007;25:1732–1740.
   PubMed Web of Science ®Google Scholar
• Sorá F, Piccirillo N, Chiusolo P, . Mitoxantrone, carboplatin, cytosine arabinoside, and methylprednisolone followed by autologous peripheral blood stem cell transplantation: a salvage regimen for patients with refractory or recurrent non-Hodgkin lymphoma. Cancer 2006;106:859–866.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Berry B, Chhanabhai M, . The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007;109:1857–1861.
   PubMed Web of Science ®Google Scholar
• Ziepert M, Hasenclever D, Kuhnt E, . Standard international prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28:2373–2380.
   PubMed Web of Science ®Google Scholar
• Haddy N, Sass C, Maumus S, . Biological variations, genetic polymorphisms and familial resemblance of TNF-alpha and IL-6 concentrations: STANISLAS cohort. Eur J Hum Genet 2005;13:109–117.
   PubMed Web of Science ®Google Scholar
• Fishman D, Faulds G, Jeffery R, . The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998;102:1369–1376.
   PubMed Web of Science ®Google Scholar
• Kilpinen S, Hulkkonen J, Wang XY, . The promoter polymorphism of the interleukin-6 gene regulates interleukin-6 production in neonates but not in adults. Eur Cytokine Netw 2001;12:62–68.
   PubMed Web of Science ®Google Scholar
• Veres A, Prohászka Z, Kilpinen S, . The promoter polymorphism of the IL-6 gene is associated with levels of antibodies to 60-kDa heat-shock proteins. Immunogenetics 2002;53:851–856.
   PubMed Web of Science ®Google Scholar
• Hegedus CM, Skibola CF, Bracci P, . Screening the human serum proteome for genotype-phenotype associations: an analysis of the IL6 -174G > C polymorphism. Proteomics 2007;7:548–557.
   PubMed Web of Science ®Google Scholar
• Taudorf S, Krabbe KS, Berg RM, . Common studied polymorphisms do not affect plasma cytokine levels upon endotoxin exposure in humans. Clin Exp Immunol 2008;152:147–152.
   PubMed Web of Science ®Google Scholar
• Latiano A, Palmieri O, Valvano MR, . Evaluating the role of the genetic variations of PTPN22, NFKB1, and FcGRIIIA genes in inflammatory bowel disease: a meta-analysis. Inflamm Bowel Dis 2007;13:1212–1219.
   PubMed Web of Science ®Google Scholar
• Riemann K, Becker L, Struwe H, . No association of the NFKB1 insertion/deletion promoter polymorphism with survival in colorectal and renal cell carcinoma as well as disease progression in B-cell chronic lymphocytic leukemia. Pharmacogenet Genomics 2006;16:783–788.
   PubMed Web of Science ®Google Scholar
• Vangsted AJ, Klausen TW, Gimsing P, . A polymorphism in NFKB1 is associated with improved effect of interferon-{alpha} maintenance treatment of patients with multiple myeloma after high-dose treatment with stem cell support. Haematologica 2009;94:1274–1281.
   PubMed Web of Science ®Google Scholar
• Ennishi D, Yokoyama M, Terui Y, . Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy. Ann Oncol 2009;20:526–533.
   PubMed Web of Science ®Google Scholar
• Mounier N, Briere J, Gisselbrecht C, . Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003;101:4279–4284.
   PubMed Web of Science ®Google Scholar
• Ott G, Ziepert M, Klapper W, . Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. Blood 2010;116:4916–4925.
   PubMed Web of Science ®Google Scholar
• Salles G, de Jong D, Xie W, . Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. Blood 2011;117:7070–7078.
   PubMed Web of Science ®Google Scholar
• Preti HA, Cabanillas F, Talpaz M, . Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma. Ann Intern Med 1997;127:186–194.
   PubMed Web of Science ®Google Scholar